FDA's personalized medicine leader Elizabeth Mansfield joined Grail, former GSK neurosciences head Atul Pande came on board with PureTech, and Zomedica…

Aveo inches closer to completing a crucial trial of its main asset tivozanib—almost four years after the FDA turned down the kidney cancer drug.

Just 12 months ago, Incyte was hit with a major trial setback when its JAK inhibition drug for solid tumors flopped a key test. Since then the biotech has been…

Cyclacel has learnt sapacitabine is no better at improving overall survival in elderly patients with AML than decitabine, triggering a 30% stock drop.

In our EuroBiotech roundup this week, Roche extends antibiotic collaboration, Big Pharma venture backs academic projects and Neovacs pens China pact.

Editors at The BMJ have warned that President Trump’s policies could damage biomedical research and regulation around the world.

Celiacs could be freed from the gluten-free aisle of the supermarket if a therapeutic approach developed by ImmusanT proves effective in trials.

Argos' cancer vaccine candidate failed a phase 3 futility analysis, wiping 65% off its stock.

New Jersey oncology biotech PMV Pharma has seen a healthy $74 million in funding from its Series B with help from InterWest Partners, Topspin Biotech Fund (…

Biotech